Edwards Lifesciences

Edwards Lifesciences is a global medical device company focused on structural heart disease. It develops, manufactures and markets artificial heart valves and hemodynamic monitoring solutions for patients with cardiovascular conditions. Its technical work spans structural heart, transcatheter heart valve technology, clinical research and advanced technology R&D.

The company pioneered Transcatheter Aortic Valve Replacement (TAVR), a method of replacing a heart valve without open-heart surgery. Its Transcatheter Heart Valve (THV) portfolio is developed in partnership with cardiologists and clinical teams and supported by rigorous clinical evidence. Alongside the THV business, Edwards' artificial heart valves and hemodynamic monitoring solutions form the core of its cardiovascular product portfolio.

Edwards reports more than 65 years of cardiovascular innovation, having served millions of patients across more than 100 countries. Its stated culture emphasises patient-focused innovation, a long-term orientation toward future solutions, and collaboration with clinical partners. Advanced Technology teams are characterised by the company as imaginative, courageous and resourceful, with an explicit commitment to innovation.